NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BRTX

BioRestorative Therapies Inc

Jul 03 • 02:45PM ET

1.55

Dollar change -0.04
Percentage change -2.52	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE AXSM FATE BLFS MESO CLPT STEM RCEL PRGO MNMD

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.51	Insider Own	27.70%	Shs Outstand	7.50M	Perf Week	-7.19%
Market Cap	11.63M	Forward P/E	-	EPS next Y	-1.08	Insider Trans	0.00%	Shs Float	5.43M	Perf Month	-12.92%
Enterprise Value	2.53M	PEG	-	EPS next Q	-0.37	Inst Own	12.62%	Short Float	4.81%	Perf Quarter	-16.22%
Income	-12.10M	P/S	29.82	EPS this Y	-44.40%	Inst Trans	-5.78%	Short Ratio	2.53	Perf Half Y	7.64%
Sales	0.39M	P/B	1.90	EPS next Y	35.52%	ROA	-85.55%	Short Interest	0.26M	Perf YTD	8.39%
Book/sh	0.82	P/C	1.28	EPS next 5Y	-	ROE	-117.16%	52W High	2.55 -39.22%	Perf Year	-21.72%
Cash/sh	1.21	P/FCF	-	EPS past 3/5Y	68.58% 78.69%	ROIC	-196.85%	52W Low	1.21 28.10%	Perf 3Y	-56.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	105.81% 25.27%	Gross Margin	41.41%	Volatility	4.74% 6.69%	Perf 5Y	287.50%
Dividend TTM	-	EV/Sales	6.49	EPS Y/Y TTM	-0.99%	Oper. Margin	-3133.88%	ATR (14)	0.10	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	2.23	Sales Y/Y TTM	161.54%	Profit Margin	-3093.59%	RSI (14)	40.71	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.23	EPS Q/Q	-91.78%	SMA20	-9.09%	Beta	76.75	Target Price	13.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-28.57%	SMA50	-9.90%	Rel Volume	0.42	Prev Close	1.59
Employees	11	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	-10.34%	Avg Volume	103.17K	Price	1.55
IPO	Jun 28, 1999	Option/Short	No / Yes	EPS/Sales Surpr.	-96.92% -93.42%	Trades		Volume	43,517	Change	-2.52%

Jun-18-25 09:35AM	BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates (GlobeNewswire)
Jun-17-25 09:25AM	BioRestorative Announces Share Repurchase Program (GlobeNewswire) +6.17%
Jun-13-25 07:45AM	BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 - an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease (GlobeNewswire) -16.00%
Jun-10-25 08:00AM	BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team (GlobeNewswire)
Jun-09-25 07:45AM	BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 (GlobeNewswire)
08:55AM	Loading…
May-15-25 08:55AM	Q1 2025 BioRestorative Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	BioRestorative Therapies Inc (BRTX) Q1 2025 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
May-14-25 06:35PM	Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-13-25 09:50AM	Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates (Zacks) -7.09%
09:15AM	Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data (GlobeNewswire)
May-12-25 05:30PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-08-25 04:30PM	BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 (GlobeNewswire)
May-07-25 09:15AM	BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 (GlobeNewswire)
Apr-15-25 08:30AM	BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities (GlobeNewswire)
09:15AM	Loading…
Apr-10-25 09:15AM	BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States (GlobeNewswire) -5.71%
Mar-27-25 08:10PM	BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-25 04:30PM	BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025 (GlobeNewswire)
Feb-27-25 09:45AM	BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain (GlobeNewswire) -15.18%
Feb-26-25 08:15PM	BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update (GlobeNewswire)
Feb-25-25 08:00AM	BioRestorative to Provide a Positive FDA Update on Clinical Pipeline (GlobeNewswire) +13.75%
Feb-20-25 08:30AM	BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program (GlobeNewswire)
Feb-10-25 07:00AM	BRTX-100 Front and Center at ORS 2025 (GlobeNewswire) +6.09%
Dec-05-24 06:45AM	BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem Metabolic Disease Program (GlobeNewswire)
Nov-13-24 07:00AM	BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data (GlobeNewswire) -6.10%
Nov-12-24 04:05PM	BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 07:00AM	BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium (GlobeNewswire) +6.45%
Nov-05-24 07:10AM	BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health (GlobeNewswire)
Oct-31-24 07:00AM	BioRestorative Therapies Receives Patent Allowance for ThermoStem Metabolic Disease Program (GlobeNewswire)
07:00AM	Loading…
Oct-10-24 07:00AM	BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events (GlobeNewswire)
Oct-03-24 04:15PM	BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-19-24 06:55AM	BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs (GlobeNewswire)
Aug-13-24 05:55PM	Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-24 04:05PM	BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024 (GlobeNewswire)
Jul-23-24 07:10AM	BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine (GlobeNewswire)
Jun-27-24 07:40AM	BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem Metabolic Disease Program (GlobeNewswire) -9.41%
Jun-17-24 07:05AM	BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results (GlobeNewswire) +20.00%
Jun-13-24 07:00AM	BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem Metabolic Disease Program (GlobeNewswire) +44.44%
Jun-12-24 08:52AM	BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +15.38%
Jun-11-24 05:50PM	Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Jun-04-24 08:50AM	BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference (GlobeNewswire) -5.43%
May-24-24 07:45PM	BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice (GlobeNewswire)
May-15-24 09:00AM	BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market (ACCESSWIRE)
May-14-24 04:10PM	BioRestorative Therapies Provides First Quarter 2024 Business Update (GlobeNewswire)
May-08-24 07:30AM	BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity (GlobeNewswire)
Apr-30-24 04:15PM	BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire) +14.52%
07:30AM	BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology (GlobeNewswire)
Apr-16-24 07:45AM	BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment (GlobeNewswire)
Apr-14-24 03:00PM	10 Micro-Cap Healthcare Stocks Insiders Are Buying (Insider Monkey)
Apr-08-24 07:45AM	BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease (GlobeNewswire)
Apr-03-24 04:38PM	BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants (GlobeNewswire)
Apr-02-24 09:53AM	BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Apr-01-24 07:45AM	BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K (GlobeNewswire)
Mar-11-24 04:15PM	BioRestorative Therapies to Participate in the 36th Annual ROTH Conference (GlobeNewswire)
Feb-14-24 09:15AM	BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting (ACCESSWIRE)
Feb-06-24 08:05AM	BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market (GlobeNewswire) -54.49%
Feb-05-24 07:30AM	BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease (GlobeNewswire) +23.21%
Feb-01-24 07:30AM	BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting (GlobeNewswire) +32.52%
Dec-12-23 09:15AM	BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program (GlobeNewswire) +5.75%
Dec-03-23 01:11PM	11 Most Volatile Stocks Under $5 For Day Trading (Insider Monkey)
Oct-09-23 12:10PM	BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City (GlobeNewswire)
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks) +15.64%
Sep-18-23 09:00AM	Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says Low Valuation Undeserved (ACCESSWIRE)
Sep-12-23 10:30AM	EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics (Benzinga) -12.37%
09:00AM	BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics (GlobeNewswire)
Sep-08-23 08:30AM	BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease (GlobeNewswire) -5.40%
Aug-30-23 09:00AM	As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs (ACCESSWIRE)
Aug-08-23 06:05PM	Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-02-23 09:00AM	BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares (ACCESSWIRE)
Jul-31-23 08:05AM	Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion (ACCESSWIRE)
Jul-26-23 01:01PM	Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX) (GuruFocus.com) +11.73%
Jul-21-23 07:10AM	BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State (ACCESSWIRE) -5.32%
Jul-11-23 08:30AM	BioRestorative Therapies Announces $2.1 Million Registered Direct Offering (GlobeNewswire) -13.20%
Jul-07-23 07:00AM	BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities (ACCESSWIRE) -7.26%
Jun-27-23 08:30AM	EXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue Unchanged (Benzinga) -23.88%
07:00AM	BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes (GlobeNewswire)
Jun-26-23 07:30AM	BioResorative CEO is Featured in An Interview With SmallCaps Daily (NewMediaWire) +13.46%
Jun-17-23 08:36AM	Is BioRestorative Therapies (NASDAQ:BRTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jun-16-23 07:00AM	BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (GlobeNewswire) +9.65%
Jun-15-23 07:48AM	Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It (ACCESSWIRE)
Jun-12-23 08:31AM	EXCLUSIVE: BioRestorative Completes Dosing In Safety Cohort Of Chronic Lower Back Pain Trial (Benzinga)
07:00AM	BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease (GlobeNewswire)
Jun-01-23 09:15AM	BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-31-23 08:30AM	EXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell Processing (Benzinga) -9.09%
07:00AM	BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing (GlobeNewswire)
May-15-23 08:31AM	EXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese Patent (Benzinga) +5.40%
07:00AM	BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program (GlobeNewswire)
May-12-23 07:15AM	A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market (ACCESSWIRE)
May-08-23 07:00AM	BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Companys Phase 2 Clinical Trial (GlobeNewswire) +17.95%
May-04-23 07:00AM	BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City (GlobeNewswire)
Apr-24-23 08:30AM	EXCLUSIVE: BioRestorative Concludes Enrollment For Safety Run-In Component Of Cell Therapy Study For Chronic Lower Back Pain (Benzinga)
07:00AM	BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100 (GlobeNewswire)
Mar-31-23 08:30AM	BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion (News Direct)
Mar-28-23 07:01AM	Bullish BioRestorative Therapies, Inc. (NASDAQ:BRTX) insiders filled their treasuries with US$593k worth of stock over last year (Simply Wall St.)
Mar-22-23 09:15AM	What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? (News Direct)
Mar-13-23 08:30AM	EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm (Benzinga)
07:00AM	BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 (GlobeNewswire)
Mar-09-23 06:30AM	BRTXs ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome (News Direct)

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Broadrick Dale	10% Owner	Oct 28 '24	Sale	1.58	1,112	1,757	445,933	Nov 05 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BRTX

BioRestorative Therapies Inc

Upgrade your FINVIZ experience